{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T15:01:51Z","timestamp":1789916511335,"version":"4.0.1"},"reference-count":34,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","seizure-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seizure: European Journal of Epilepsy"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.seizure.2026.07.012","type":"journal-article","created":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T05:46:33Z","timestamp":1783921593000},"page":"109-115","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Cenobamate in older adults with drug-resistant epilepsy: Real-world tolerability, efficacy, and predictors of discontinuation"],"prefix":"10.1016","volume":"141","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1078-9167","authenticated-orcid":false,"given":"Yeo Jun","family":"Yoon","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8291-7864","authenticated-orcid":false,"given":"Rani","family":"Sarkis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5283-7476","authenticated-orcid":false,"given":"Jong Woo","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.seizure.2026.07.012_bib0001","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1007\/s40266-026-01283-z","article-title":"Antiseizure medications in older adults with epilepsy: considerations in pharmacology, safety, tolerability, and effectiveness of newer agents","volume":"43","author":"McCarthy","year":"2026","journal-title":"Drugs Aging"},{"issue":"6","key":"10.1016\/j.seizure.2026.07.012_bib0002","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1007\/s40263-021-00819-8","article-title":"Pharmacology of cenobamate: mechanism of action, pharmacokinetics, drug-drug interactions and tolerability","volume":"35","author":"Roberti","year":"2021","journal-title":"CNS Drugs"},{"issue":"11","key":"10.1016\/j.seizure.2026.07.012_bib0003","doi-asserted-by":"crossref","first-page":"2329","DOI":"10.1111\/epi.16718","article-title":"Cenobamate (XCOPRI): can preclinical and clinical evidence provide insight into its mechanism of action?","volume":"61","author":"Guignet","year":"2020","journal-title":"Epilepsia"},{"key":"10.1016\/j.seizure.2026.07.012_bib0004","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.ejphar.2019.05.007","article-title":"Effects of cenobamate (YKP3089), a newly developed anti-epileptic drug, on voltage-gated sodium channels in rat hippocampal CA3 neurons","volume":"855","author":"Nakamura","year":"2019","journal-title":"Eur J Pharmacol"},{"issue":"22","key":"10.1016\/j.seizure.2026.07.012_bib0005","doi-asserted-by":"crossref","first-page":"e2311","DOI":"10.1212\/WNL.0000000000009530","article-title":"Randomized phase 2 study of adjunctive cenobamate in patients with uncontrolled focal seizures","volume":"94","author":"Chung","year":"2020","journal-title":"Neurology"},{"issue":"1","key":"10.1016\/j.seizure.2026.07.012_bib0006","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/S1474-4422(19)30399-0","article-title":"Safety and efficacy of adjunctive cenobamate (YKP3089) in patients with uncontrolled focal seizures: a multicentre, double-blind, randomised, placebo-controlled, dose-response trial","volume":"19","author":"Krauss","year":"2020","journal-title":"Lancet Neurol"},{"issue":"3","key":"10.1016\/j.seizure.2026.07.012_bib0007","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1007\/s40266-024-01102-3","article-title":"Safety and efficacy of cenobamate for the treatment of focal seizures in older patients: post hoc analysis of a phase III, multicenter, open-label study","volume":"41","author":"O\u2019Dwyer","year":"2024","journal-title":"Drugs Aging"},{"key":"10.1016\/j.seizure.2026.07.012_bib0008","series-title":"Proceedings of the 2016 international conference on management of data","first-page":"215","article-title":"The snowflake elastic data warehouse","author":"Dageville","year":"2016"},{"issue":"5","key":"10.1016\/j.seizure.2026.07.012_bib0009","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/0021-9681(87)90171-8","article-title":"A new method of classifying prognostic comorbidity in longitudinal studies: development and validation","volume":"40","author":"Charlson","year":"1987","journal-title":"J Chronic Dis"},{"issue":"5","key":"10.1016\/j.seizure.2026.07.012_bib0010","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1001\/jamaneurol.2020.0032","article-title":"Tolerability of antiseizure medications in individuals with newly diagnosed epilepsy","volume":"77","author":"Alsfouk","year":"2020","journal-title":"JAMA Neurol"},{"issue":"1","key":"10.1016\/j.seizure.2026.07.012_bib0011","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1007\/s40801-020-00216-5","article-title":"Association between adverse events and discontinuation of antiepileptic drugs among drug-na\u00efve adults with epilepsy","volume":"8","author":"Peasah","year":"2021","journal-title":"Drugs Real World Outcomes"},{"issue":"1","key":"10.1016\/j.seizure.2026.07.012_bib0012","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1159\/000521288","article-title":"Charlson comorbidity index: a critical review of clinimetric properties","volume":"91","author":"Charlson","year":"2022","journal-title":"Psychother Psychosom"},{"issue":"11","key":"10.1016\/j.seizure.2026.07.012_bib0013","first-page":"e1135","article-title":"Association between frailty and antiseizure medication tolerability in older adults with epilepsy","volume":"100","author":"Vary-O\u2019Neal","year":"2023","journal-title":"Neurology"},{"issue":"6","key":"10.1016\/j.seizure.2026.07.012_bib0014","doi-asserted-by":"crossref","first-page":"2128","DOI":"10.1002\/epi4.13046","article-title":"The implications of frailty in older adults with epilepsy","volume":"9","author":"Hashmi","year":"2024","journal-title":"Epilepsia Open"},{"issue":"4","key":"10.1016\/j.seizure.2026.07.012_bib0015","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1177\/15357597231178072","article-title":"Start low and go slow: the general principle of managing older adults with epilepsy finds robust support from frailty","volume":"23","author":"Punia","year":"2023","journal-title":"Epilepsy Curr"},{"issue":"6","key":"10.1016\/j.seizure.2026.07.012_bib0016","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1111\/epi.16525","article-title":"Cenobamate (YKP3089) as adjunctive treatment for uncontrolled focal seizures in a large, phase 3, multicenter, open-label safety study","volume":"61","author":"Sperling","year":"2020","journal-title":"Epilepsia"},{"key":"10.1016\/j.seizure.2026.07.012_bib0017","series-title":"XCOPRI (cenobamate) tablets [prescribing information]","year":"2025"},{"key":"10.1016\/j.seizure.2026.07.012_bib0018","unstructured":"European Medicines Agency. New safety information for healthcare professionals : ontozry (cenobamate): new requirements for liver monitoring due to reports of severe liver injury [Internet]. 2026 [cited 2026 May 8]. Available from: https:\/\/www.ema.europa.eu\/en\/news\/meeting-highlights-pharmacovigilance-risk-assessment-committee-prac-7-10-april-2026."},{"key":"10.1016\/j.seizure.2026.07.012_bib0019","doi-asserted-by":"crossref","DOI":"10.1177\/17562864241256733","article-title":"Therapeutic strategies during cenobamate treatment initiation: Delphi panel recommendations","volume":"17","author":"Steinhoff","year":"2024","journal-title":"Ther Adv Neurol Disord"},{"issue":"4","key":"10.1016\/j.seizure.2026.07.012_bib0020","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1111\/epi.17935","article-title":"A global update on cenobamate based on real-world experience in over 100 000 patients","volume":"65","author":"Ferrari","year":"2024","journal-title":"Epilepsia"},{"issue":"10","key":"10.1016\/j.seizure.2026.07.012_bib0021","doi-asserted-by":"crossref","first-page":"2909","DOI":"10.1111\/epi.18091","article-title":"Adjunctive cenobamate in people with focal onset seizures: insights from the Italian expanded access program","volume":"65","author":"Roberti","year":"2024","journal-title":"Epilepsia"},{"issue":"3","key":"10.1016\/j.seizure.2026.07.012_bib0022","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1111\/epi.70006","article-title":"Impact of long-term treatment with cenobamate on concomitant usage of antiseizure medications: a real-world retrospective study in Spain","volume":"67","author":"S\u00e1nchez-Caro","year":"2026","journal-title":"Epilepsia"},{"issue":"5","key":"10.1016\/j.seizure.2026.07.012_bib0023","doi-asserted-by":"crossref","DOI":"10.1002\/brb3.70567","article-title":"Cenobamate in real-world scenario: results on efficacy, side effects, and retention rate in a single center retrospective study","volume":"15","author":"Badr","year":"2025","journal-title":"Brain Behav"},{"key":"10.1016\/j.seizure.2026.07.012_bib0024","doi-asserted-by":"crossref","DOI":"10.1016\/j.yebeh.2025.110464","article-title":"Steps towards seizure freedom with the use of cenobamate","volume":"170","author":"Toledo","year":"2025","journal-title":"Epilepsy Behav"},{"issue":"4","key":"10.1016\/j.seizure.2026.07.012_bib0025","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1001\/jamaneurol.2025.5625","article-title":"Comparative effectiveness of brivaracetam, cenobamate, lacosamide, and perampanel in focal epilepsy","volume":"83","author":"Cerulli Irelli","year":"2026","journal-title":"JAMA Neurol"},{"issue":"1","key":"10.1016\/j.seizure.2026.07.012_bib0026","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1111\/epi.17134","article-title":"Long-term individual retention with cenobamate in adults with focal seizures: pooled data from the clinical development program","volume":"63","author":"Sander","year":"2022","journal-title":"Epilepsia"},{"issue":"10","key":"10.1016\/j.seizure.2026.07.012_bib0027","doi-asserted-by":"crossref","first-page":"e989","DOI":"10.1212\/WNL.0000000000200792","article-title":"Long-term efficacy and safety from an open-label extension of adjunctive cenobamate in patients with uncontrolled focal seizures","volume":"99","author":"Klein","year":"2022","journal-title":"Neurology"},{"issue":"3","key":"10.1016\/j.seizure.2026.07.012_bib0028","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1038\/s43587-021-00043-5","article-title":"Healthy aging and the blood-brain barrier","volume":"1","author":"Banks","year":"2021","journal-title":"Nat Aging"},{"issue":"8","key":"10.1016\/j.seizure.2026.07.012_bib0029","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1007\/s40262-017-0614-5","article-title":"Effect of age-related factors on the pharmacokinetics of lamotrigine and potential implications for maintenance dose optimisation in future clinical trials","volume":"57","author":"van Dijkman","year":"2018","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.seizure.2026.07.012_bib0030","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.seizure.2024.08.021","article-title":"The aging brain and late onset drug-refractory epilepsies","volume":"128","author":"Potschka","year":"2025","journal-title":"Seizure"},{"issue":"9","key":"10.1016\/j.seizure.2026.07.012_bib0031","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1007\/s40263-021-00827-8","article-title":"The pharmacology and clinical efficacy of antiseizure medications: from bromide salts to cenobamate and beyond","volume":"35","author":"L\u00f6scher","year":"2021","journal-title":"CNS Drugs"},{"issue":"5","key":"10.1016\/j.seizure.2026.07.012_bib0032","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1111\/epi.17549","article-title":"Adjunctive cenobamate in highly active and ultra-refractory focal epilepsy: a \u201creal-world\u201d retrospective study","volume":"64","author":"Pe\u00f1a-Ceballos","year":"2023","journal-title":"Epilepsia"},{"issue":"9","key":"10.1016\/j.seizure.2026.07.012_bib0033","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1007\/s40263-025-01196-2","article-title":"The effects of cenobamate and its dosage on cognition: a retrospective longitudinal study in 84 individuals with epilepsy","volume":"39","author":"Witt","year":"2025","journal-title":"CNS Drugs"},{"issue":"2","key":"10.1016\/j.seizure.2026.07.012_bib0034","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1007\/s40265-021-01661-4","article-title":"Third-generation antiseizure medications for adjunctive treatment of focal-onset seizures in adults: a systematic review and network meta-analysis","volume":"82","author":"Lattanzi","year":"2022","journal-title":"Drugs"}],"container-title":["Seizure: European Journal of Epilepsy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1059131126002104?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1059131126002104?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T14:25:39Z","timestamp":1789914339000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1059131126002104"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":34,"alternative-id":["S1059131126002104"],"URL":"https:\/\/doi.org\/10.1016\/j.seizure.2026.07.012","relation":{},"ISSN":["1059-1311"],"issn-type":[{"value":"1059-1311","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cenobamate in older adults with drug-resistant epilepsy: Real-world tolerability, efficacy, and predictors of discontinuation","name":"articletitle","label":"Article Title"},{"value":"Seizure: European Journal of Epilepsy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.seizure.2026.07.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 British Epilepsy Association. Published by Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}